cr8

(R)-CR8 trihydrochloride (CR8, (R)-Isomer trihydrochloride) is a CDK1/2/5/7/9 inhibitor that acts as a molecular glue degrader with neuroprotective activity and induces apoptosis.

(R)-CR8 ((R)-Isomer) is a potent and selective CDK inhibitor.

(S)-CR8 is an effective second-generation cyclin-dependent kinase inhibitor.

CCR8 agonist1 (Compound 2) is an activator of CCR8 and is applicable in studies related to autoimmune diseases.

CCR8 antagonist 2 is a potent inhibitor of CCR8 (C-C Motif chemokine receptor 8), predominantly expressed on Treg and Th2 cells, and not on Th1 cells. CCR8 antagonist 2 can be used for the treatment of CCR8-mediated diseases (e.g., cancer and/or neuropathic pain).

CCR8 antagonist 3 (compound 2), a potent inhibitor of CCR8, exhibits an IC 50 value of 0.062 µM and demonstrates stability in human microsomes [1].

Anti-CCR8 Antibody (10A11) is a humanized IgG1 monoclonal antibody targeting CCR8.

CCR8 antagonist 1 is an antagonist of C-C Motif Chemokine Receptor 8 (CCR8) with a Ki value of 1.6 nM.